Viral Weight Loss Drug Linked to Vision Loss
Imagine having your doctor prescribe the “latest, greatest” prescription drug that promises the impossible…
Weight loss in a shot.
The fact that it’s FDA-approved and widely popular might make you think it’s completely safe.
Spoiler alert… It isn’t.
Evidence has been mounting against these drugs for years, and now we have another casualty to add to the list.
By now, I’m sure you’ve heard about semaglutide. It’s the viral GLP-1 agonist drug that goes by the brand names Ozempic, Wegovy, and Saxenda.
These drugs were initially designed to treat type 2 diabetes, but the FDA has now approved them for weight loss as well.
I’ll admit… they’re VERY good at helping people lose weight.
By reducing appetite, slowing digestion, and stimulating insulin release, GLP-1s can help people lose 15-20 percent of their body weight or more.
But at what cost?
Studies reveal the harsh reality. When compared to other weight loss drugs, GLP-1s are associated with…
- 9 times higher risk of pancreatitis
- 22 times higher risk of bowel obstruction
- 67 times higher risk of gastroparesis (stomach paralysis)
These serious side effects can dramatically impact your health and quality of life.
But wait, there’s more. A new study has confirmed that semaglutide is linked to a higher risk of vision impairment.
Researchers analyzed over 300,000 reports from the FDA’s Adverse Events Reporting System (AERS). They found that semaglutide had significantly more reports of vision impairment or optic neuropathy than other antidiabetic and weight-loss medications.
It’s easy to think that “rare” side effects won’t happen to you—especially when the doctor pushing the drugs highlights the benefits while downplaying the risks.
However, with each new study on semaglutide, this becomes more difficult. GLP-1 drugs simply aren’t worth the risk.
P.S. Warning! New side effect of “viral” weight loss drugs is revealed.
View Sources
Massy, M., Marti, S., Hammer, H. et al. Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data. BMC Med 23, 203 (2025).
